Related to Fast Forward and JDRF Team Up with Axxam for MS and Diabetes Treatments

• Monash University Collaborates with Cryo-Cell to Investigate Menstrual Stem Cell Therapy for MS
  
• Canada Grants GW Pharm’s Sativex Full Approval for MS Spasticity
  
• Russian Authorities Become First to Sanction Novartis’ Oral MS Therapy
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• Novartis Gets FDA OK for MS Therapy and Makes Headway against Cushing Disease
  
• UC San Diego Gets $5M for Induced Pluripotent Stem Cell Research in Type 1 Diabetes
  
• Sanofi-Aventis’ Teriflunomide Comes Up Trumps in Two-Year Phase III MS Trial
  
• MacroGenics and Lilly Ponder Future of Diabetes mAb after Phase III Flop
  
• Biogen Idec and Genentech Tweak Anti-CD20 Alliance to Prevent Future Squabbles
  
• Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research
  
• Biogen Idec Restructuring Will Close Sites & Divest Cancer Assets to Save $300M a Year
  
• Accentia Secures Rights to Baxter’s Cyclophosphamide for Autoimmune Candidate
  
• Phase III Trial Demonstrates Benefits of Teva’s Laquinimod in MS Patients
  
• Approval of MannKind’s Inhaled Insulin Further Delayed
  
• CHMP Upholds Previous Negative Opinion on Merck KGaA’s MS Therapy
  
• Biogen Idec’s Fampyra for MS Fails to Win CHMP Support in Europe
  
• Novartis Wins Positive Recommendation for Its MS Drug from CHMP
  
• Switzerland and Australia Approve Novartis’ MS Drug
  
• Nuron Chooses the Merck BioManufacturing Network for Phase III MS Candidate
  
• Sanofi-Aventis and Genzyme Finally Agree to $20.1B plus CVR Acquisition Deal